Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2026-03-13 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about the closure of the trading window in compliance with insider trading regulations. It references the upcoming declaration of audited financial results but does not contain any financial data or the results themselves. The document is a regulatory announcement related to trading restrictions rather than a financial report or earnings release. Given its brevity (1287 characters) and nature as a notification, it fits best under Regulatory Filings (RNS).
2026-03-13 English
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the closure of the trading window in compliance with insider trading regulations. It mentions the trading window closure period related to the declaration of audited financial results but does not contain any financial data, results, or detailed report content. The document is an announcement related to regulatory compliance and trading restrictions rather than a financial report or detailed filing. Given its brevity (1287 characters) and nature as a notification, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2026-03-13 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, Mrs. Sandhya Tejaswini Amanna, as Director - Legal. It references compliance with SEBI Listing Regulations and provides detailed information about the appointment, including the effective date and a brief profile. There are no financial statements, earnings data, or report attachments. The content clearly fits the category of announcements related to changes in senior management or board members. Therefore, the document is best classified as Board/Management Information (MANG). The document length is 3340 characters, which is consistent with a detailed announcement rather than a full report or a brief notice.
2026-03-11 English
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, Mrs. Sandhya Tejaswini Amanna, as Director - Legal. It references compliance with SEBI Listing Regulations and provides detailed information about the appointment, including the effective date and a brief profile. There are no financial statements, earnings data, or report attachments. The content clearly fits the category of announcements related to changes in senior management or board members. Therefore, the document is best classified as Board/Management Information (MANG). The document length is 3340 characters, which is consistent with a detailed announcement rather than a full report or a brief notice.
2026-03-11 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice dated February 11, 2026, sent to shareholders of AstraZeneca Pharma India Limited. It details the process for remote e-voting on special business resolutions, including approval of material related party transactions. The document includes instructions for voting, dates for the voting period, and references to compliance with the Companies Act, SEBI Listing Regulations, and MCA Circulars. It is not a report of voting results, nor a management or financial report, but a notice to shareholders to solicit their votes via postal ballot (electronic voting). This fits the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings or resolutions. The document is lengthy (15,000 characters) and contains detailed explanatory statements and voting instructions, consistent with PSI filings.
2026-02-27 English
Please find the enclosed Postal Ballot Notice dated February 11, 2026 for your reference.
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice dated February 11, 2026, sent to shareholders of AstraZeneca Pharma India Limited. It details the process for remote e-voting on special business resolutions, including approval of material related party transactions. The document includes instructions for voting, dates for the voting period, and references to regulatory compliance under the Companies Act, SEBI Listing Regulations, and MCA Circulars. It is not a report of voting results, nor a management or financial report, but a notice seeking shareholder approval via postal ballot. This fits the category of Proxy Solicitation & Information Statement (PSI), as it is a material sent to shareholders to provide information and request votes for a meeting or resolution.
2026-02-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.